Dr. Gradishar Discusses Dual HER2-Targeting in Breast Cancer

William J. Gradishar, MD
Published: Tuesday, Oct 17, 2017



William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses dual HER2-targeting in breast cancer.

Trastuzumab (Herceptin) is used in different settings in the treatment of patients with HER2-positive breast cancer.

There is a trend forming, says Gradishar, as dual HER2-targeting is being used first in the preoperative, postoperative, and early in the sequence for patients with metastatic disease.
 
SELECTED
LANGUAGE


William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses dual HER2-targeting in breast cancer.

Trastuzumab (Herceptin) is used in different settings in the treatment of patients with HER2-positive breast cancer.

There is a trend forming, says Gradishar, as dual HER2-targeting is being used first in the preoperative, postoperative, and early in the sequence for patients with metastatic disease.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x